Antonio Llombart Cussac MD, PhD
is Chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain and Associate Professor in the Catholic University of Valencia.
He received his medical school training in Pamplona and Valencia (from 1982 to 1989). He did his training in medical oncology at the University Hospital in Valencia (from 1999 to 1993). After that, he performed a 4 year fellowship (1994 to 1997) in the Breast Cancer Unit at Institute Gustave Roussy (Villejuif, France) focusing on new drugs (phase I and II studies); becoming a medical staff member from 1995 to 1997. From 1997 to 2005 he was attached to the Department of Medical Oncology at the Instituto Valenciano de Oncologia. In 2003 was promoted to the Head of the Breast Cancer Research Unit.
Between September 2005 to August 2010, he has led the Medical Oncology Service at the University Hospital Arnau de Vilanova in Lleida, Spain. He obtained is PhD degree in Breast Cancer in 2005. Since 2010, he is coordinating a clinical unit integrated by pharmacologists, surgeons, pathologists and biologists from several centers working with cytotoxic and molecular agents both in human and animal models. His major present focus is on translational clinical trials and correlative science in the preoperative management of breast and endometrial cancer patients.
Dr. Llombart is the President and Co-founder of the company Medica Scientia Innovation Research (MedSIR ARO), an academic research organization focused in the scientific knowledge activity and clinical research development (www.medsir.org). This company conducts the independent clinical trials created by own Scientific Committee – MERIBEL trial (Eribulin first line MBC), TRASTYVERE study, POEM (temsirolimus in endometrial carcinoma, etc…) – and clinical trials in collaboration with pharmaceutical companies or international cooperative groups (NSABP-FB7, Phase I TDM1, POLEN trial, NABUCO trial), focused on oncology setting.
He is actively involved in many international co-operative groups and trials. He is principal investigator in NEO-PARP (NCT01204125) trial, PAMELA trial (Molecular signature trastuzumab + Lapatinib), VICTORIA Study (Vinflunine phase III first line) and GEICAM/2009-02 (NCT01298193). Since 2012, he is president in SOLTI breast cancer group.
Antonio Llombart develops a consultant activity in Oncology area and breast cancer for several pharmaceutical companies: Eli Lilly and company (USA), Novartis pharmaceutical, Pfizer Oncology Spain and Boehringer Ingelheim. He is member of International Scientific Committee for P024 study (letrozol in neoadjuvant treatment), for ZO-FAST study and International expert of the clinical investigation committee for breast cancer (local and advanced). Institut National du Cancer (INCA), Paris, France (2005 a 2007).
He is author of more than 80 publications and he is member of Editorial Board of the journal “Oncologia, La revue francophone de formation en oncologia” since 2004 and Board Member of Sociedad Española de Oncología Médica (2005 a 2009).